Skip to main content
Download PDF

Volume 7 Supplement 1

16th International Symposium on HIV and Emerging Infectious Diseases

Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study

Retrovirology volume 7, Article number: P63 (2010) Cite this article

Background

Protease inhibitors based antiretroviral therapy has been associated with elevated plasma insulin levels and insulin resistance. HCV infections are an independent risk factor for diabetes development. In vitro Atazanavir (ATV) has shown minimal inhibitory effect on the insulin-regulated glucose transporter GLUT4. Studies in healthy HIV-negative demonstrated a favorable metabolic profile. Clinical studies in HIV and HCV/HIV coinfected pretreated patients with underlying real conditions are needed.

Methods

51 pretreated HIV-1 infected patients who started ATV/r were included prospectively. Insulin resistance was assessed by HOMA (Homeostasis Model Assesment). Hepatotoxicity was defined according to AIDS Clinical Trials Group criteria to ALT values. Clinical data and laboratory parameters were analyzed at baseline and every 12 weeks up to 48. It includes body mass index (BMI), fasting glucose, insulin, triglycerides (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), CD4+ cell count and HIV-1 RNA. HIV monoinfected and HIV/HCV co-infected (pos HCV-RNA) patients were compared.

Results

23 HIV-mono and 28 HIV-HCV coinfected patients were analyzed. Mean age was 40 ± 8 years, male 74%; median CD4 count (IQR) 288 (224-548) cells/μL. 53% plasma HIV-RNA<50 copies/mL. Only 1 case of severe hepatotoxicity (Grade 4) was seen (coinfected patient). Metabolic profile is shown in Table 1. ATV was discontinuated in 4 cases (2 poor adherence and 2 gastrointestinal intolerance). Non virological or immunological failures were documented.

Table 1 Table 1
Full size table

Discussion

ATV/r can be safely used in patients with chronic viral hepatitis. ATV/r regimens do not induce insulin resistence and has a good lipid profile in coinfected as in monoinfected patients. These results would be better with unboosted ATV regimens.

Author information

Affiliations

  1. HIV Unit, Internal Medicine Service, Universitary Hospital of A Coruña, A Coruña, Spain

    Héctor Meijide, Álvaro Mena, Ángeles Castro, Pilar Vázquez, Soledad López, Joaquín Serrano, Laura Bello & José Pedreira

  2. University of A Coruña, A Coruña, Spain

    Ángeles Castro

Authors
  1. Héctor Meijide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Álvaro Mena
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ángeles Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Pilar Vázquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soledad López
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Joaquín Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Laura Bello
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. José Pedreira
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Álvaro Mena.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Meijide, H., Mena, Á., Castro, Á. et al. Effects on insulin sensitivity and hepatic safety of Atazanavir in HCV/HIV coinfected patients versus HIV monoinfected: A prostective 48-week study. Retrovirology 7, P63 (2010). https://doi.org/10.1186/1742-4690-7-S1-P63

Download citation

Keywords

  • Atazanavir
  • AIDS Clinical Trial Group
  • Glucose Transporter GLUT4
  • Include Body Mass Index
  • Immunological Failure

Retrovirology

ISSN: 1742-4690

Contact us